Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens

DSpace/Manakin Repository

Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens

Citable link to this page

 

 
Title: Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens
Author: Cramer, Daniel William; Bast, R. C.; Berg, C. D.; Diamandis, E. P.; Godwin, A. K.; Hartge, P.; Lokshin, A. E.; Lu, K. H.; McIntosh, M. W.; Mor, G.; Patriotis, C.; Pinsky, P. F.; Thornquist, M. D.; Scholler, N.; Skates, Steven James; Sluss, Patrick M.; Srivastava, S.; Ward, D. C.; Zhang, Z.; Zhu, C. S.; Urban, N.

Note: Order does not necessarily reflect citation order of authors.

Citation: Cramer, D. W., R. C. Bast, C. D. Berg, E. P. Diamandis, A. K. Godwin, P. Hartge, A. E. Lokshin, et al. 2011. “Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens.” Cancer Prevention Research 4 (3) (March 1): 365–374. doi:10.1158/1940-6207.capr-10-0195.
Full Text & Related Files:
Abstract: Establishing a cancer screening biomarker’s intended performance requires “phase III” specimens obtained in asymptomatic individuals before clinical diagnosis rather than “phase II” specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets.

Phase II specimens from 180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network (EDRN) or Ovarian Cancer Specialized Program of Research Excellence (SPORE) sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls.

Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity when moving to phase III specimens that had been drawn within six months of the clinical diagnosis. Performance of all markers declined in phase III specimens more remote than 6 months from diagnosis.

Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study.
Published Version: doi:10.1158/1940-6207.CAPR-10-0195
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085251/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27336542
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters